Thread by @GorwayGlobal

Will @MoHFW_INDIA or @CDSCO_INDIA_INF put out an explanatory note to deal with all the questions about the differences in approval for
a) @SerumInstIndia's #Covishield
b) @BharatBiotech's #Covaxin
pib.gov.in/PressReleseDet…

For Covishield:
"restricted emergency use of vaccine, subject to multiple regulatory conditionalities"
For Covaxin
"restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, specially in the context of infection by mutant strains

One interpretation of the Covaxin approval is that it is essentially approval to continue their phase 3 trial. In which case, what's new?
Then, a day later, i.e. today we learn: pib.gov.in/PressReleseDet…

This press release says, of Covaxin, "The Phase III efficacy trial was initiated in India in 25,800 volunteers and till date, ~22,500 participants have been vaccinated across the country and the vaccine has been found to be safe as per the data available till date."

The 22,500 can't have been 'vaccinated' this was a placebo study so half must have got the placebo. Be that as it may, we know from Bharat Bioptech's press release of 16 Nov, that they started their Phase 3 trial in Mid Nov. bharatbiotech.com/images/press/B…

We further @BharatBiotech's press release on 22 Dec "announced successful recruitment of 13,000
volunteers..." see this link,
bharatbiotech.com/images/press/c…

So here's the Question: when did 13,000 volunteers recruited as of 22 Dec turn into 22,500 (out of a target 26,000) by the time @CDSCO_INDIA_INF's expert committee looked at the data.